» Authors » Peter Lin

Peter Lin

Explore the profile of Peter Lin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 141
Citations 2439
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Ramos C, Bonasera D, Saggau J, Kabiljo J, Lin P, Tishina S, et al.
Biochim Biophys Acta Mol Cell Res . 2024 Jan; 1871(3):119677. PMID: 38266659
The 12th Tuscany Retreat on Cancer Research and Apoptosis was held on August 19-26, 2023. The biennial retreat aims to bring together scientists who advance research in cancer, cell death,...
12.
Hofman M, Emmett L, Sandhu S, Iravani A, Buteau J, Joshua A, et al.
Lancet Oncol . 2023 Dec; 25(1):99-107. PMID: 38043558
Background: The TheraP study reported improved prostate-specific antigen responses with lutetium-177 [Lu]Lu-PSMA-617 versus cabazitaxel in men with metastatic castration-resistant prostate cancer progressing after docetaxel. In this Article, we report the...
13.
Lin P, Lourenco C, Cruickshank J, Palomero L, van Leeuwen J, Tong A, et al.
Cancer Res . 2023 Nov; 83(24):4015-4029. PMID: 37987734
Significance: CRISPR screening reveals topoisomerase 1 as an immediately actionable vulnerability in cancers harboring MYC as a driver oncoprotein that can be targeted with clinically approved inhibitors.
14.
Patel M, Lin P, Cheng Q, Argon N, Evans C, Linthicum B, et al.
Am J Emerg Med . 2023 Nov; 76:29-35. PMID: 37980725
Objectives: There is limited evidence on sex, racial, and ethnic disparities in Emergency Department (ED) triage across diverse settings. We evaluated differences in the assignment of Emergency Severity Index (ESI)...
15.
Wang W, Tasset A, Pyatnitskiy I, Lin P, Bellamkonda A, Mehta R, et al.
Nano Lett . 2023 Oct; 23(20):9310-9318. PMID: 37843021
Nonviral gene delivery has emerged as a promising technology for gene therapy. Nonetheless, these approaches often face challenges, primarily associated with lower efficiency, which can be attributed to the inefficient...
16.
Barry N, Francis R, Ebert M, Koh E, Rowshanfarzad P, Hassan G, et al.
Eur J Nucl Med Mol Imaging . 2023 Aug; 50(13):3970-3981. PMID: 37563351
Purpose: The O-(2-[F]-fluoroethyl)-L-tyrosine (FET) PET in Glioblastoma (FIG) trial is an Australian prospective, multi-centre study evaluating FET PET for glioblastoma patient management. FET PET imaging timepoints are pre-chemoradiotherapy (FET1), 1-month...
17.
Trada Y, Keall P, Jameson M, Moses D, Lin P, Chlap P, et al.
Eur Radiol . 2023 Jul; 33(12):8788-8799. PMID: 37405500
Objectives: To test if tumour changes measured using combination of diffusion-weighted imaging (DWI) MRI and FDG-PET/CT performed serially during radiotherapy (RT) in mucosal head and neck carcinoma can predict treatment...
18.
Taboun Z, Naik N, Brown V, Lin P, Padarath M, Hegele R, et al.
CJC Open . 2023 Jun; 5(5):357-363. PMID: 37377517
Background: Cardiovascular (CV) risk management for high-risk patients is often provided by primary care physicians (PCPs). We surveyed Canadian PCPs regarding their awareness and implementation of the 2021 Canadian Cardiovascular...
19.
Trada Y, Lee M, Jameson M, Chlap P, Keall P, Moses D, et al.
Radiother Oncol . 2023 Jun; 186:109745. PMID: 37330056
Background: The aim of this study was to measure functional changes in parotid glands using mid-treatment FDG-PET/CT and correlate early imaging changes to subsequent xerostomia in mucosal head and neck...
20.
Trada Y, Lin P, Lee M, Jameson M, Chlap P, Keall P, et al.
Quant Imaging Med Surg . 2023 May; 13(5):2822-2836. PMID: 37179931
Background: The aim of this study was to evaluate the impact of tumour region of interest (ROI) delineation method on mid-treatment F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) response prediction in mucosal...